PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Apr 21, 2016
SOUTH PLAINFIELD, N.J., April 21, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Thursday, May 5, 2016 at 4:30 p.m. (ET) after the closing of the market. ...
Apr 15, 2016
SOUTH PLAINFIELD, N.J., April 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna ∇ (ataluren) for ambulatory patients aged five years and older with nonsense mutation Duchenne muscular dystrophy (nmDMD) in connection with ...
Mar 23, 2016
SOUTH PLAINFIELD, N.J., March 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S.  This reduction is part of PTC's program intended to optimally manage operating expenses following its recent ...
Mar 14, 2016
SOUTH PLAINFIELD, N.J., March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for Translarna™ (ataluren) to treat nonsense mutation Duchenne muscular...
Mar 14, 2016
SOUTH PLAINFIELD, N.J., March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) will be presented at the 5th International Congres...
Mar 2, 2016
SOUTH PLAINFIELD, N.J., March 2, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2016 it approved non-statutory stock options to purchase an aggregate of 29,500 shares of its common stock to 12 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ...
Feb 29, 2016
SOUTH PLAINFIELD, N.J., Feb. 29, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2015. "We are shocked and disappointed to have received a Refuse to File (RTF) letter from the FDA regarding our NDA for Transl...
Feb 26, 2016
SOUTH PLAINFIELD, N.J., Feb. 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has had multiple discussions with the German Federal Association of the Statutory Health Insurances (GKV-SV) over the last several months to come to agreement on pricing and reimbursement.  Recently, these discussions transit...
Feb 23, 2016
SOUTH PLAINFIELD, N.J., Feb. 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC's New Drug Application (NDA) for Translarna™ (ataluren), an oral, first-in-class, protein restoration the...
Feb 15, 2016
SOUTH PLAINFIELD, N.J., Feb. 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2015 financial results and provide an update on the company's business and outlook on Monday, February 29, 2016 at 4:30 p.m. (ET) after the closing...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue